There is no established MOTS-c cycle. No published protocol says eight weeks on and four weeks off, or anything close to it, because no study has ever tested a MOTS-c schedule with an off period in it. The word arrived from bodybuilding, where cycling means deliberately pausing a hormone so the body's own production can start back up. MOTS-c is not that kind of drug, and the research that exists ran it straight through. What a prescriber sets instead is a length of time and a date to look at how you are doing.
If your question is how much rather than how long, MOTS-c dosage covers that one separately.
Where “cycling” came from, and why it doesn't carry over
Cycling is a steroid idea. Take testosterone from outside and the body notices: the signal from the brain that tells the testes to make their own tails off. Come off for a while and that signal is meant to recover. The off-weeks have a job.
Nothing like that has been shown for MOTS-c. Your mitochondria make it themselves, and levels rise after exercise — but nobody has shown that giving it from outside shuts that production down, or that a pause restores anything. FDA's reviewers went further: the molecular target MOTS-c acts through is still unknown, which makes it hard even to predict which organs it reaches.
So when a forum post lays out five days on, two days off, eight weeks and then a break, that shape is borrowed — from a different class of drug, with a different problem to solve. Nobody invented it to mislead you. It just doesn't come from anything anyone measured about MOTS-c.
How long the studies actually ran
Here's the part with real numbers in it. It's short.
Most of the durations live in the mouse work. In the 2015 paper that first described the peptide, mice got daily injections for seven days in the insulin experiments, and eight weeks of daily treatment in the high-fat-diet experiment (Cell Metabolism). A 2021 study in Nature Communications gave middle-aged and old mice daily injections for two weeks, and found that ten days of treatment improved running capacity in high-fat-diet mice where seven days had not — about the only direct sign anywhere that duration by itself changes the result.
That study also holds the closest thing to an intermittent schedule anywhere in the literature — and it's worth seeing what it was. In its longest arm, old mice were injected daily, then moved after eight weeks to three times a week, and stayed on that until they were past 30 months old, close to the end of their lives. That isn't a cycle. It's a step down to a maintenance rhythm that never stopped.
In people the record is thinner. A MOTS-c analogue called CB4211 went through a Phase 1 study: one injection a day for seven days in healthy volunteers, then one a day for 28 days in twenty people with fatty liver disease (NCT03998514). A Phase 2a trial of the peptide itself opened in February 2026 and is enrolling 120 adults with prediabetes — a fixed dose once daily for 12 weeks, safety followed out to week 16 (NCT07505745).
| Study | Who | How it was given | For how long |
|---|---|---|---|
| Cell Metabolism, 2015 | Mice | Once daily | 7 days; 8 weeks in the diet study |
| Nature Communications, 2021 | Mice | Daily, then 3x a week | 2 weeks; longest arm ran past 30 months of age |
| CB4211 Phase 1 (an analogue) | People | Once daily | 7 days, then 28 days |
| Phase 2a, now enrolling | People | Once daily | 12 weeks |
Not one of them has an off period in it.
Why there is no evidence-based MOTS-c cycle
To design a cycle you need three things: how fast the drug clears, how long an effect takes to show up, and how long it lasts once you stop. For MOTS-c in people, none of the three has been measured.
FDA said as much directly. In an evaluation dated 11 May 2026, written for the compounding advisory committee that met in July, the agency reported no clinical studies and no human exposure data for MOTS-c by any route, and no studies of how it is absorbed or cleared in a living animal. The one related finding it could point to was a test-tube experiment in which MOTS-c broke down quickly in human blood — which raised the question of whether injecting it leaves enough intact peptide to act at all (FDA briefing document).
That review weighed against adding MOTS-c to the list of substances pharmacies may use in compounded medicines under section 503A, and the agency has not issued a final determination. MOTS-c is dispensed as a compounded medication and is not FDA-approved. None of that decides anything about one person's case: a licensed provider may still prescribe a compounded formulation, and that decision is between you and your doctor.
It helps to see the alternative. SS-31, the other mitochondria-targeted peptide in this category, has people in a Phase 3 trial injecting it daily for 96 weeks, with the main measurement read at week 48 (NCT06373731). Nearly two years, continuously — and that is what a duration answer looks like once somebody has done the work to produce one.
What the newest research adds
As of September 6, 2026, the day this article was written, the two most recent MOTS-c papers both make the duration question harder rather than easier.
In June 2026, a Mayo Clinic group reported in Inflammation and Regeneration that adding MOTS-c to human stem cells from people with obesity did switch on the metabolic signaling it's known for — and at the same time slowed how well those cells multiplied, raised two markers of cellular aging, and blunted their ability to repair injured tissue in mice. Cells in a dish are not a person. But it is a direct demonstration that more MOTS-c signal is not automatically better, which is the quiet assumption underneath any long open-ended run.
Then in August 2026, the lab that discovered the peptide published in eLife that MOTS-c also acts as a host defense molecule: it killed E. coli and MRSA in culture, and reprogrammed mouse immune cells. Ten years on, what MOTS-c even is is still being revised. That's not an argument against it. It's an argument for a short first run and a real conversation, rather than a schedule copied off a forum.
How a provider decides how long you stay on it
With no protocol to follow, duration is a clinical judgment rather than a number. A prescriber works backwards from the shortest run that could answer the question being asked.
That means naming, before anything is dispensed, what you would expect to notice and roughly when. It means a scheduled review — a real appointment, not a refill button — where you say what has and hasn't changed. It means checking whatever in your history the compound could touch. And it means being willing to stop, which is the part people tend to skip.
Not everyone qualifies for MOTS-c in the first place: a licensed provider reads your history and either prescribes or declines, and a decline is a normal outcome rather than a failure of the process. How often you inject is a separate question — how often peptides are injected takes that one — and so is what to watch for along the way, which MOTS-c side effects covers.
What happens when you stop
Honestly, in people, nobody knows.
The mouse studies measured effects while treatment was still going, and the arm that ran longest never stopped at all. There is no published washout data for MOTS-c in humans, and no measurement of how long anything persists after a last dose, because there is no published human dosing study to take it from.
Anyone quoting you a figure for how long the benefits last after a cycle ends is making it up. The honest version is that stopping is a decision you make with the person who prescribed it, and the thing you watch is yourself.